NASDAQ:BLFS BioLife Solutions (BLFS) Stock Price, News & Analysis → Only buy and sell these 100 stocks (From DTI) (Ad) Free BLFS Stock Alerts $21.26 -0.22 (-1.02%) (As of 05:23 PM ET) Add Compare Share Share Today's Range$20.75▼$21.8050-Day Range$15.14▼$22.9952-Week Range$8.92▼$24.50Volume214,910 shsAverage Volume416,145 shsMarket Capitalization$978.60 millionP/E RatioN/ADividend YieldN/APrice Target$23.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get BioLife Solutions alerts: Email Address BioLife Solutions MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside12.2% Upside$23.67 Price TargetShort InterestBearish8.73% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.46Based on 12 Articles This WeekInsider TradingSelling Shares$601,896 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.50) to ($0.14) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.85 out of 5 starsMedical Sector843rd out of 924 stocksElectromedical Equipment Industry17th out of 20 stocks 2.5 Analyst's Opinion Consensus RatingBioLife Solutions has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageBioLife Solutions has only been the subject of 2 research reports in the past 90 days.Read more about BioLife Solutions' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted8.73% of the outstanding shares of BioLife Solutions have been sold short.Short Interest Ratio / Days to CoverBioLife Solutions has a short interest ratio ("days to cover") of 9.5.Change versus previous monthShort interest in BioLife Solutions has recently increased by 12.92%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldBioLife Solutions does not currently pay a dividend.Dividend GrowthBioLife Solutions does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BLFS. Previous Next 1.9 News and Social Media Coverage News SentimentBioLife Solutions has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.77 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for BioLife Solutions this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for BLFS on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BioLife Solutions insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $601,896.00 in company stock.Percentage Held by InsidersOnly 2.70% of the stock of BioLife Solutions is held by insiders.Percentage Held by Institutions93.24% of the stock of BioLife Solutions is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about BioLife Solutions' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for BioLife Solutions are expected to grow in the coming year, from ($0.50) to ($0.14) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioLife Solutions is -14.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioLife Solutions is -14.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBioLife Solutions has a P/B Ratio of 2.75. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about BioLife Solutions' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad The TradingPubDon’t buy Gold until you see this Did you know gold has “hotspot dates” between December 12th - December 24th? Meaning it’s gone up on average during those dates for the past 34 YEARS! Most people probably have no clue about these dates unless they have access to this former hedge fund manager's Data Mining Software…. As you can see, it would have alerted you ahead of time that gold was gearing up for a big move between these dates.But if you want the stock with “Hotspot Dates” hitting NEXT WEEK… About BioLife Solutions Stock (NASDAQ:BLFS)BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.Read More BLFS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BLFS Stock News HeadlinesJune 1 at 9:41 AM | insidertrades.comInsider Selling: BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Sells 517 Shares of StockJune 2 at 9:08 AM | americanbankingnews.comAby J. Mathew Sells 517 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS) StockJune 2 at 8:32 AM | americanbankingnews.comBioLife Solutions, Inc. (NASDAQ:BLFS) CFO Sells $12,501.72 in StockMay 29, 2024 | prnewswire.comBioLife Solutions Introduces the CellSeal CryoCase™ at International Society for Cell & Gene Therapies (ISCT) Conference in VancouverMay 18, 2024 | finance.yahoo.comInsider Sale: Chief Marketing Officer Todd Berard Sells 10,000 Shares of BioLife Solutions Inc ...May 14, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Fennec Pharmaceuticals (FENC) and BioLife Solutions (BLFS)May 14, 2024 | msn.comBenchmark Upgrades BioLife Solutions (BLFS)May 12, 2024 | finance.yahoo.comAnalysts Are Upgrading BioLife Solutions, Inc. (NASDAQ:BLFS) After Its Latest ResultsMay 10, 2024 | finance.yahoo.comBioLife Solutions, Inc. (NASDAQ:BLFS) Q1 2024 Earnings Call TranscriptMay 10, 2024 | finanznachrichten.deBioLife Solutions, Inc.: BioLife Solutions Reports First Quarter 2024 Financial ResultsMay 9, 2024 | markets.businessinsider.comBLFS Stock Earnings: BioLife Solns Beats EPS, Beats Revenue for Q1 2024May 9, 2024 | investing.comBioLife Solutions Inc (BLFS)May 9, 2024 | msn.comBioLife Solutions GAAP EPS of -$0.22, revenue of $31.7MMay 9, 2024 | prnewswire.comBioLife Solutions Reports First Quarter 2024 Financial ResultsApril 30, 2024 | prnewswire.comBioLife Solutions to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024April 25, 2024 | investing.comBiolife Solutions exec sells shares worth over $8,900April 25, 2024 | investing.comBiolife Solutions exec sells shares worth over $5,000April 20, 2024 | investing.comBioLife Solutions divests Stirling freezer subsidiaryApril 20, 2024 | msn.comBioLife Solutions divest stirling freezer business to reduce cash burnApril 19, 2024 | bizjournals.comBioLife Solutions lays off 47 workers after divesting cold storage businessApril 18, 2024 | finance.yahoo.comInsider Sell: Chief Marketing Officer Todd Berard Sells 10,000 Shares of BioLife Solutions Inc ...April 18, 2024 | prnewswire.comBioLife Solutions Announces the Divestiture of its Stirling Freezer BusinessApril 4, 2024 | markets.businessinsider.comBuy Rating on BioLife Solutions: Focused Growth and Market Leadership Post-DivestitureMarch 30, 2024 | msn.comPowell: ‘No reason’ to think economy is close to recessionMarch 29, 2024 | finance.yahoo.comInvestors in BioLife Solutions (NASDAQ:BLFS) have unfortunately lost 49% over the last three yearsSee More Headlines Receive BLFS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioLife Solutions and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today6/03/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Electromedical equipment Sub-IndustryN/A Current SymbolNASDAQ:BLFS CUSIPN/A CIK834365 Webwww.biolifesolutions.com Phone(425) 402-1400Fax425-402-1433Employees409Year FoundedN/APrice Target and Rating Average Stock Price Target$23.67 High Stock Price Target$25.00 Low Stock Price Target$22.00 Potential Upside/Downside+10.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.42) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-66,430,000.00 Net Margins-45.84% Pretax Margin-45.69% Return on Equity-12.89% Return on Assets-10.53% Debt Debt-to-Equity Ratio0.05 Current Ratio2.89 Quick Ratio1.77 Sales & Book Value Annual Sales$143.27 million Price / Sales6.90 Cash FlowN/A Price / Cash FlowN/A Book Value$7.67 per share Price / Book2.80Miscellaneous Outstanding Shares46,030,000Free Float44,788,000Market Cap$988.72 million OptionableOptionable Beta1.80 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Roderick de Greef (Age 64)CEO & Chairman Comp: $1.63MMr. Troy Wichterman (Age 39)Chief Financial Officer Comp: $485.2kMs. Karen Foster (Age 64)Chief Quality & Operations Officer Comp: $395.2kDr. Aby J. Mathew Ph.D. (Age 52)Chairman of Scientific Advisory Board, Executive VP & Chief Scientific Officer Comp: $448.2kMr. Todd Berard (Age 55)Chief Marketing Officer Comp: $286.49kMs. Sarah Aebersold J.D. (Age 47)Chief Human Resources Officer Mr. Garrie Richardson B.Sc. (Age 51)M.B.A., Chief Revenue Officer More ExecutivesKey CompetitorsNatus MedicalNASDAQ:NTUSIntegerNYSE:ITGRLivaNovaNASDAQ:LIVNCONMEDNYSE:CNMDInModeNASDAQ:INMDView All CompetitorsInsiders & InstitutionsAby J MathewSold 517 sharesTotal: $11,260.26 ($21.78/share)Karen A FosterSold 408 sharesTotal: $8,886.24 ($21.78/share)Troy WichtermanSold 574 sharesTotal: $12,501.72 ($21.78/share)Todd BerardSold 345 sharesTotal: $7,514.10 ($21.78/share)Troy WichtermanSold 115 sharesTotal: $2,550.70 ($22.18/share)View All Insider TransactionsView All Institutional Transactions BLFS Stock Analysis - Frequently Asked Questions Should I buy or sell BioLife Solutions stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioLife Solutions in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BLFS shares. View BLFS analyst ratings or view top-rated stocks. What is BioLife Solutions' stock price target for 2024? 5 brokers have issued 1 year target prices for BioLife Solutions' shares. Their BLFS share price targets range from $22.00 to $25.00. On average, they anticipate the company's share price to reach $23.67 in the next twelve months. This suggests a possible upside of 12.2% from the stock's current price. View analysts price targets for BLFS or view top-rated stocks among Wall Street analysts. How have BLFS shares performed in 2024? BioLife Solutions' stock was trading at $16.25 at the beginning of 2024. Since then, BLFS shares have increased by 29.8% and is now trading at $21.09. View the best growth stocks for 2024 here. Are investors shorting BioLife Solutions? BioLife Solutions saw a increase in short interest in May. As of May 15th, there was short interest totaling 4,020,000 shares, an increase of 12.9% from the April 30th total of 3,560,000 shares. Based on an average daily volume of 423,600 shares, the days-to-cover ratio is presently 9.5 days. View BioLife Solutions' Short Interest. When is BioLife Solutions' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our BLFS earnings forecast. How were BioLife Solutions' earnings last quarter? BioLife Solutions, Inc. (NASDAQ:BLFS) announced its quarterly earnings results on Thursday, May, 9th. The medical equipment provider reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.06. The medical equipment provider had revenue of $31.73 million for the quarter, compared to analysts' expectations of $29.30 million. BioLife Solutions had a negative trailing twelve-month return on equity of 12.89% and a negative net margin of 45.84%. During the same quarter in the previous year, the business earned ($0.27) earnings per share. What guidance has BioLife Solutions issued on next quarter's earnings? BioLife Solutions issued an update on its FY 2024 earnings guidance on Thursday, May, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $95.5 million-$100.0 million, compared to the consensus revenue estimate of $105.7 million. What is Mike Rice's approval rating as BioLife Solutions' CEO? 14 employees have rated BioLife Solutions Chief Executive Officer Mike Rice on Glassdoor.com. Mike Rice has an approval rating of 100% among the company's employees. This puts Mike Rice in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 89.0% of employees surveyed would recommend working at BioLife Solutions to a friend. What other stocks do shareholders of BioLife Solutions own? Based on aggregate information from My MarketBeat watchlists, some companies that other BioLife Solutions investors own include Micron Technology (MU), AbbVie (ABBV), Cara Therapeutics (CARA), Gilead Sciences (GILD), Pfizer (PFE), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Twilio (TWLO) and Verastem (VSTM). Who are BioLife Solutions' major shareholders? BioLife Solutions' stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (6.33%), William Blair Investment Management LLC (3.81%), Geneva Capital Management LLC (1.94%), Gagnon Securities LLC (1.31%), Russell Investments Group Ltd. (0.43%) and Principal Financial Group Inc. (0.42%). Insiders that own company stock include Aby J Mathew, Aby J Mathew, Amy Duross, Andrew G Hinson, Andrew G Hinson, Casdin Partners Master Fund, L, Geraint Phillips, Greef Roderick De, Joseph C Schick, Karen A Foster, Karen A Foster, Marcus Schulz, Michael Rice, Sarah Aebersold, Todd Berard and Troy Wichterman. View institutional ownership trends. How do I buy shares of BioLife Solutions? Shares of BLFS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BLFS) was last updated on 6/3/2024 by MarketBeat.com Staff From Our PartnersNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemWeiss RatingsThe Only Energy Play You Should Be Looking AtWealthpin Pro[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 MediaNext President (Not Trump. Not Biden.)The Freeport SocietyCollapse of the Petrodollar Colonial Metals[Webinar] Understanding Covered CallsOICWhat’s Pelosi Buying Now?AltimetryAlex's "Next Magnificent Seven" StocksThe Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioLife Solutions, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.